Effect of Early Administration of TXA in Adult Hip Fractures
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Tranexamic acid.
- Who it may be relevant to
- Registry conditions: Postoperative Blood Loss. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Does Early Administration of Tranexamic Acid Decrease Perioperative Blood Loss in Addition to Intraoperative Tranexamic Acid for Hip Fracture Patients?
Overview
This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.
Interventions
- Drug Tranexamic acid
TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
Primary outcome measures
- Postoperative Blood Transfusion [Time frame: Up to two weeks]
- Overall Blood Loss [Time frame: Up to two weeks]
Secondary outcome measures (4)
- Length of hospital stay [Time frame: Up to two weeks]
- Postoperative Pain [Time frame: Up to two weeks]
- Wound complications [Time frame: Up to two weeks]
- Acute DVT/PE [Time frame: Up to two weeks]
Eligibility criteria
Inclusion criteria
- 1\. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation
Exclusion criteria
- Polytrauma patients
- Previous operation on the ipsilateral hip
- Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)
- Patients with < 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)
- History of seizure disorder
- Patients on birth control
- Pregnant Women
- Prisoners
- Active thromboembolic disease (DVT/PE, MI, Stroke)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
United States · 1 center
- Ascension Genesys Hospital — Grand Blanc
Identifiers
NCT: NCT05047133 · 1722787-1